Top payer group shoots down Gilead's hep C drug Sovaldi on price

Gilead's Sovaldi--Courtesy of Gilead

Individual payers aren't alone in balking at the $84,000 price for Gilead Sciences' ($GILD) new hepatitis C treatment Sovaldi. Now, the leading insurance trade group has joined the soloists, backing their complaints with its own. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.